STOCK TITAN

Cocrystal Pharma Inc - COCP STOCK NEWS

Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.

About Cocrystal Pharma Inc.

Cocrystal Pharma Inc. (NASDAQ: COCP) is a cutting-edge biotechnology company dedicated to the discovery and development of novel antiviral therapeutics. The company's mission is to address serious and chronic viral diseases by leveraging advanced drug discovery technologies and Nobel Prize-winning expertise. Operating within the highly specialized pharmaceutical and biotechnology industry, Cocrystal focuses on creating first- and best-in-class antiviral drugs targeting unmet medical needs in areas such as hepatitis, influenza, and norovirus infections.

Core Business and Technology

At the heart of Cocrystal Pharma's operations is its proprietary structure-based drug design platform. This innovative approach allows the company to efficiently develop small-molecule antiviral therapeutics that are not only safe and effective but also convenient to administer. The company's expertise in nucleoside chemistry further strengthens its ability to create groundbreaking therapeutics. By targeting the replication machinery of viruses, Cocrystal aims to deliver antiviral drugs that disrupt the disease process at its core, offering significant advantages over traditional therapies.

Key Therapeutic Areas

  • Hepatitis: Cocrystal is actively developing antiviral compounds aimed at addressing the unmet needs of patients with hepatitis infections. By focusing on innovative mechanisms of action, the company seeks to provide effective treatment options for this widespread and chronic disease.
  • Influenza: The company is working on antiviral therapeutics that target influenza viruses, with the goal of reducing the global burden of seasonal and pandemic influenza outbreaks. Its investigational treatments aim to offer broad-spectrum efficacy and improved safety profiles.
  • Norovirus: Recognizing the lack of effective treatments for norovirus infections, Cocrystal is advancing preclinical-stage compounds designed to address this significant unmet medical need.

Strategic Partnerships and Industry Validation

Cocrystal Pharma has garnered strategic investments from prominent industry players, including Teva Pharmaceuticals, OPKO Health, and the Frost Group. These partnerships not only provide financial support but also validate the company's innovative approach to antiviral drug discovery. Additionally, the involvement of Dr. Raymond Schinazi, a renowned expert in antiviral research, underscores the company’s commitment to scientific excellence and its strong foundation in cutting-edge research.

Market Position and Competitive Landscape

Operating in the competitive pharmaceutical industry, Cocrystal Pharma differentiates itself through its structure-based drug design and focus on high-impact therapeutic areas. The company faces competition from established pharmaceutical giants and emerging biotech firms, but its innovative technologies and partnerships give it a unique edge. By addressing unmet medical needs and leveraging its expertise, Cocrystal aims to carve out a significant niche in the antiviral therapeutics market.

Challenges and Opportunities

As a company focused on preclinical and early-stage drug development, Cocrystal faces challenges such as long development timelines, regulatory hurdles, and the need for sustained funding. However, its strategic focus on high-burden diseases and its ability to attract industry-leading partners position it well to capitalize on growth opportunities. The global demand for effective antiviral therapies continues to rise, providing a strong market backdrop for the company’s innovations.

Conclusion

Cocrystal Pharma Inc. represents a promising player in the biotechnology sector, with a clear focus on addressing critical unmet medical needs in the antiviral therapeutics space. By combining advanced technologies, scientific expertise, and strategic partnerships, the company is well-positioned to make significant contributions to the treatment of viral diseases. While challenges remain, Cocrystal's innovative approach and commitment to scientific excellence underscore its potential to deliver transformative therapies that improve patient outcomes worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (COCP) announced the appointment of Fred Hassan to its Board of Directors, expanding the board to six members. Hassan brings over 40 years of experience in the pharmaceutical industry, having held senior roles at major companies and investment firms. His recent $2 million investment in Cocrystal via an at-the-market private placement underscores his confidence in the company's prospects.

The Chairman of the Board, Roger Kornberg, expressed optimism that Hassan's expertise will strengthen corporate governance and help advance Cocrystal's antiviral pipeline. Hassan emphasized the company's potential to develop innovative antiviral therapies using a unique structure-based discovery platform. This announcement signals a strategic move for Cocrystal as it aims to enhance its leadership and drive its research efforts towards commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
management
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) announces the acceptance of an oral presentation of new data from its CC-42344 Phase 1 influenza A study at the 7th Annual ISIRV Antiviral Group Conference on May 4, 2023. Dr. Sam Lee, President and co-CEO, will present insights on the first-in-human study of CC-42344, a novel broad-spectrum influenza A polymerase PB2 inhibitor. The company anticipates filing for regulatory approval for a Phase 2a human challenge study later in 2023. CC-42344 has shown potent antiviral activity against various influenza A strains, including those resistant to existing treatments like Tamiflu and Xofluza.

This presentation aligns with the conference theme, “Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19.” Cocrystal plans to summarize the data presented and share slides on its website after the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences clinical trial
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a private placement of 2,030,458 shares of common stock at $1.97 per share, raising $4.0 million. The investment was made by notable industry leaders Phillip Frost, M.D., and Fred Hassan, each contributing $2.0 million. This capital infusion strengthens Cocrystal's financial position as it prepares for significant clinical milestones. The company is set to commence a Phase 2a human challenge study for its PB2 inhibitor CC-42344 and a first-in-human trial for its COVID-19 protease inhibitor CDI-988, both pending regulatory approvals. Additionally, a lead candidate in the norovirus program is expected to be selected by mid-2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) reported financial results for the year ending December 31, 2022, revealing a net loss of $38.8 million, or $4.77 per share, up from $14.2 million, or $0.16 per share in 2021. R&D expenses increased to $12.4 million as the company advanced its antiviral pipeline, including the CC-42344 Phase 1 trial and upcoming CDI-988 Phase 1 trial. Cocrystal plans to submit UK and Australian regulatory filings for influenza and COVID-19 studies, respectively. The company reported unrestricted cash of $37.1 million as of December 31, 2022, with working capital at $39 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that CFO and co-CEO James Martin will present at the Virtual Investor Summit Conference on March 29, 2023, at 10:30 a.m. Eastern time. The presentation will highlight significant advancements and upcoming milestones in their antiviral programs targeting influenza A, COVID-19, and norovirus. The company employs innovative structure-based technologies to develop novel antiviral therapeutics aimed at viral replication processes.

For more details, interested parties can register for the presentation online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
none
Rhea-AI Summary

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced its participation in several upcoming virtual investment community events. Co-CEO and CFO James Martin will be featured in the Noble Capital Markets’ J.P. Morgan Healthcare Conference Takeaways, available January 26, discussing the biotechnology market and Cocrystal’s opportunities. Additionally, an update on the company’s influenza and COVID-19 antiviral programs will be presented in the C-Suite Interview Series by February 1. Cocrystal will also present at Sequire’s Virtual Biotechnology Conference on February 2 at 11:30 a.m. ET. Cocrystal specializes in developing antiviral therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) reported positive results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study demonstrated favorable safety and tolerability, with no serious adverse events reported. Approximately 50% of subjects experienced mild adverse events, similar to the placebo group. The company plans to apply for regulatory approval to initiate a Phase 2a study in early 2023, targeting potential treatments for pandemic and seasonal influenza, aiming to address significant healthcare costs associated with the illness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.34%
Tags
-
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) has presented progress on its CC-42344 influenza treatment at the World Antiviral Congress 2022. The Phase 1 study results indicate a favorable safety profile and potential clinical benefits against various influenza A strains. Plans are underway to report topline results by year-end 2022 and initiate a Phase 2a human challenge trial in 2023. The drug, a PB2 inhibitor, shows promise against seasonal and pandemic strains, notably with a high barrier to resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
none
Rhea-AI Summary

Cocrystal Pharma (Nasdaq: COCP) announced positive results from the ongoing Phase 1 study of CC-42344, an oral antiviral for influenza A, showing a favorable safety profile in both single-ascending and multiple-ascending dose portions. The trial supports once-daily dosing, with topline results expected by the end of 2022. CC-42344 targets all major influenza A strains, demonstrating excellent antiviral activity. The company plans to submit an application for a Phase 2a human challenge study in early 2023, aiming to initiate the trial in the second half of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags

FAQ

What is the current stock price of Cocrystal Pharma (COCP)?

The current stock price of Cocrystal Pharma (COCP) is $1.42 as of April 4, 2025.

What is the market cap of Cocrystal Pharma (COCP)?

The market cap of Cocrystal Pharma (COCP) is approximately 14.4M.

What does Cocrystal Pharma Inc. focus on?

Cocrystal Pharma focuses on discovering and developing antiviral therapeutics for serious and chronic viral diseases, including hepatitis, influenza, and norovirus.

What technologies does Cocrystal Pharma use?

The company employs structure-based drug design and nucleoside chemistry expertise to develop first- and best-in-class antiviral drugs.

Who are Cocrystal Pharma's strategic partners?

Cocrystal has received investments from Teva Pharmaceuticals, OPKO Health, the Frost Group, and Dr. Raymond Schinazi, among others.

What are the key challenges for Cocrystal Pharma?

Key challenges include long drug development timelines, regulatory hurdles, and the need for sustained funding to advance preclinical and early-stage compounds.

How does Cocrystal Pharma differentiate itself from competitors?

Cocrystal leverages advanced structure-based drug design, Nobel Prize-winning expertise, and a focus on unmet medical needs to stand out in the antiviral therapeutics market.

What diseases does Cocrystal Pharma target?

The company targets viral diseases such as hepatitis, influenza, and norovirus, focusing on areas with significant unmet medical needs.

What is the significance of nucleoside chemistry in Cocrystal's work?

Nucleoside chemistry expertise enables Cocrystal to design small-molecule therapeutics that effectively target viral replication mechanisms.

What stage are Cocrystal Pharma's drug candidates in?

Cocrystal Pharma’s drug candidates are primarily in the preclinical and early development stages, focusing on innovative antiviral compounds.
Cocrystal Pharma Inc

Nasdaq:COCP

COCP Rankings

COCP Stock Data

14.40M
6.93M
31.85%
6.99%
0.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOTHELL